Inside Precision Medicine

Clinical OMICs has transformed into Inside Precision Medicine. Inside Precision Medicine stands as the sole global media outlet dedicated to covering all aspects of precision medicine. It takes a broad view while also delving into the intricate and interconnected challenges that shape this field. With its main magazine, real-time website, a range of eNewsletters, and a variety of engaging broadcast events and multimedia content, Inside Precision Medicine serves as the essential platform for robust discussions and insights that encompass technological advancements as well as complex socio-economic and public policy matters. It also aims to provide practical solutions to the gaps that exist among various stakeholders. Inside Precision Medicine is committed to innovative thinking and actively contributing to genuine progress and change, with a focus on enhancing and streamlining the precision medicine process for the benefit of patients in need. Our main focus areas include Translational Research, Molecular Diagnostics, Informatics, and Patient Care, alongside broader coverage of Disease Indications and Payer/Regulatory topics. Our top-notch content is designed to inform, educate, and enlighten a diverse audience of researchers, pathologists, clinicians, executives, and other professionals in the field.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#449608

United States

#195262

Health/Health Conditions and Concerns

#484

Traffic sources

Monthly visitors

Articles

First Cancer Trial Targeting “Undruggable” MYC Launching

1 week ago | insideprecisionmedicine.com | Malorye Allison Branca

“A world-first” clinical trial targeting currently undruggable cancers will begin later this year led by a research team from The Australian National University (ANU) and Canberra Health Services. The trial targets MYC-driven cancers—including prostate, breast, ovarian, and hematological malignancies. MYC is a key regulator of cell growth. The drug being tested is PMR-116.
Spatial Transcriptomic Analysis Highlights Genetic Adaptability of Glioblastoma

1 week ago | insideprecisionmedicine.com | Laura Cowen

Researchers have used spatial transcriptomics to identify subpopulations of glioblastomas that carry specific genetic alterations in different regions of the tumor, including in extrachromosomal DNA (ecDNA), which may contribute to the tumor’s ability to adapt and become more aggressive.
Incyte Partners with Qiagen to Create Diagnostic for Rare Blood Cancers

1 week ago | insideprecisionmedicine.com | Helen Albert

Rare blood cancer specialist Incyte has announced it will partner with diagnostic test expert Qiagen to create a sequencing panel to accompany several investigative therapies being developed by Incyte to treat rare blood cancers.
Extracellular Vesicle Diagnostic Platform Launched by Mursla Bio

1 week ago | insideprecisionmedicine.com | Helen Albert

U.K. biotech Mursla Bio has launched an artificial intelligence (AI)-based platform that can diagnose and monitor cancers based on data from extracellular vesicles—small, membrane-bound particles released by almost all types of cells—in the blood. The company was launched in 2019 and specializes in detection and analysis of extracellular vesicle data from different organs.
Nuravax Alzheimer’s Vaccine to Amyloid-Beta Is Safe, Immunogenic in Phase 1

1 week ago | insideprecisionmedicine.com | Jonathan Grinstein

After years of steadily advancing his career as an investment director in the European life sciences, Roman Kniazev took the bold but necessary step to begin navigating the turbulent biotech innovation landscape. “I realized that until you truly experience the agony of being a biotech entrepreneur, you cannot make wise investments,” Kniazev told Inside Precision Medicine.
Founder’s Nonprofit TTAM to Acquire 23andMe in Surprise Turnaround

1 week ago | insideprecisionmedicine.com | Helen Albert

Anne Wojcicki, co-founder and former CEO of direct-to-consumer genetic testing company 23andMe, has succeeded in a bid to buy almost all the assets of the bankrupt company through a nonprofit set up by Wojcicki in May this year called TTAM.
Harnessing AI Innovation to Modernize Clinical Trials

2 weeks ago | insideprecisionmedicine.com | Helen Albert |Kathy Vuksanaj

Clinical trials are an essential part of bringing new medicines to patients but are often slow and expensive to complete. Innovations in artificial intelligence (AI) over the last two decades are already having a positive impact on the way these trials are run and have the potential to improve them further in many ways, ranging from simple economics to more diverse trial cohorts.
Best Kept Secret-Ome: Juvena Therapeutics and Lilly Partner on Muscle Health

2 weeks ago | insideprecisionmedicine.com | Jonathan Grinstein

Drug development platforms are always spawning in the endless fight for superiority—there is always a bigger fish with more, for example, throughput or training data. Once in a while, a novel platform class is born, and that’s what Hanadie Yousef, PhD, has done by introducing the world’s first AI-enabled screening platform focused on mapping secreted proteins. This isn’t a bigger fish—it’s an entirely new ecosystem.
Nonsense! Engineered tRNAs Offer Universal Solutions to Stop Codon Diseases

2 weeks ago | insideprecisionmedicine.com | Jonathan Grinstein

Jonathan D. Grinstein, PhD, the North American Editor of Inside Precision Medicine, hosts a new series called Behind the Breakthroughs that features the people shaping the future of medicine. With each episode, Jonathan gives listeners access to their motivational tales and visions for this emerging, game-changing field. In May of 2020, drug developer Michelle Werner learned that one of her three children, her middle child Caffrey, was diagnosed with Duchenne muscular dystrophy (DMD).
Fresh Evidence that Microplastics Raise Colorectal Cancer Risk

2 weeks ago | insideprecisionmedicine.com | Malorye Allison Branca

Microplastics (MPs), we are learning, are everywhere and implicated in a growing number of cancers. Now, a Chinese team has new evidence that they cause colorectal cancer (CRC). This study identified MPs in both peritumoral and tumor tissues of colorectal cancer patients, highlighting their accumulation in human cancers. Previous research has shown MP accumulation in other human organs, such as the lungs and liver.